ENYO Pharma SA
ENYO Pharma is a clinical-stage biopharmaceutical company dedicated to developing highly differentiated therapeutics for improving the quality of life of patients with impaired kidney function. Their lead compound, Vonafexor, is in Phase 2 development for rare kidney disease Alport Syndrome and Chronic Kidney Diseases (CKD). The company focuses on fibrolytic and anti-inflammatory properties in organs such as kidney and liver, and also addresses liver-related infectious diseases like Hepatitis B and D.
Industries
Nr. of Employees
small (1-50)
ENYO Pharma SA
Products
Oral small-molecule FXR agonist (lead clinical compound)
A synthetic non-steroidal small-molecule agonist of the farnesoid X receptor developed for oral once-daily administration; preferential tissue distribution to kidney and liver with reported fibrolytic and anti-inflammatory activity and ongoing Phase 2 clinical development for kidney and liver indications.
Oral small-molecule FXR agonist (lead clinical compound)
A synthetic non-steroidal small-molecule agonist of the farnesoid X receptor developed for oral once-daily administration; preferential tissue distribution to kidney and liver with reported fibrolytic and anti-inflammatory activity and ongoing Phase 2 clinical development for kidney and liver indications.
Services
Collaborative drug development and licensing
Partnerships and licensing arrangements to advance therapeutic candidates through non-clinical and clinical development, and joint research collaborations with academic and industry partners.
Collaborative drug development and licensing
Partnerships and licensing arrangements to advance therapeutic candidates through non-clinical and clinical development, and joint research collaborations with academic and industry partners.
Expertise Areas
- Clinical trial management (Phase 2)
- Nuclear receptor (FXR) small-molecule therapeutics
- Biomimetic drug discovery
- Bioinformatics and omics analysis
Key Technologies
- FXR (NR1H4) agonist pharmacology
- Small-molecule drug discovery
- Oral tablet formulation development
- Virus-host protein interaction analysis